FibroBiologics, Inc. (FBLG)

FibroBiologics Files Patent Application for Technology Designed to Produce GLP-1 and Other Therapeutic Peptides Inside the Body

FibroBiologics Announces Grant of European Patent for Methods of Enhancing Fibroblast Therapeutic Activity

FibroBiologics, Inc. (FBLG) Discusses Strategy and Clinical Progress in Fibroblast-Based Cell Therapies for Chronic Diseases Transcript

FibroBiologics Announces Closing of $0.5 Million Private Placement with Chief Scientific Officer

FibroBiologics Announces Issuance of New U.S. Patent for the Therapeutic Use of Fibroblasts in Wound Healing

FibroBiologics Announces Issuance of New U.S. Patent for the Treatment of Degenerative Disc Disease Using Fibroblast Conditioned Media

FibroBiologics advances diabetic ulcer trial with new drug shipment to Australia

FibroBiologics Releases Third Batch of CYWC628 Drug Product for Phase 1/2 Diabetic Foot Ulcer Clinical Trial

FibroBiologics Regains Compliance with Nasdaq Trading Rules

FibroBiologics Appoints Leigh Steinberg to Board of Directors

FibroBiologics Announces Australian Patent Accepted for Cannabidiol Adjuvant Therapy for the Treatment of Degenerative Disc Disease

FibroBiologics Says Preclinical Data Shapes Design of Further Studies for Degenerative Joint Treatment

FibroBiologics Announces Chondrocyte Spheroids Demonstrate Cartilage Repair in Preclinical Study of Degenerative Joints

FibroBiologics Granted U.S. Patent Covering the Use of Fibroblasts to Enhance Survival and Function of Transplanted Insulin-Producing Islets

FibroBiologics Granted European Patent Covering Gene Therapy for the Regeneration of Cartilage

FibroBiologics Reports Second Quarter 2026 Financial Results; Progresses Clinical Trial Evaluating Lead Wound Care Candidate